Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I was going to mention is this one of those low dosage trials?
I remember a poster mentioned his condition cleared up.
Since it is an inflammatory condition why not? What is the external cause of the condition or is it genetic? I was not aware of the condition until it was mentioned here. My family has been in good health until very old age with the usual old age problems hips and backs still living. I joke about my mom all the time, she’s a heavy coffee drinker. I till my family even if she dies her body will probably be animated. They won’t even know she’s dead! ??
I think it boils down to is equal ratio of EPA/AA a signature for good health. EPA/AA test should become common place in the PCP's office. Prescription to patients who have unbalanced ratios.
Thanks! I wonder if a Patent has been filed regarding treatment of NASH? Another marketing possibility. A trial seems like it is in order.
So Amarin has not been collecting RWD which include patient data from various sources 'EMR'S/Pharmacies/Insurance Companies' over the last few years?
Seem like your out of touch!
Do you think Reduce-It will have picked up on reduction of Liver Fat and inflammation? Is there a specific test to detect liver inflammation or fat levels?
I think a poster or two mention liver fat reduction while taking Vascepa.
Prove I am wrong....O.K. let play it your way. Amarin is flying by the seat of their pants regarding weight loss. Once again all you want to do is argue...
Do me a favor mind your own business!
RWD....and research.
At this point it's an educated guess. I hope we see data released from Reduce-It to backup the Patent regarding weight loss. It would be nice if they PR recent activity regarding Patents. A number of posters observed weight loss after a couple of years taking Vascepa including myself. But real proof is in the numbers.
Your missing the pieces of the puzzle as usual. Amarin has in published data in hand!
Not likely! I’m thinking Real World Data see Amarin investor relations regarding a couple of related subjects TG’ and Diabetes. This is data mined from insurance databases over the years of patients prescribed VASCEPA.
Think positive! Why would they file a patent unless they thought otherwise?
I don't remember if the case came to completion, I remember something about AZN pulling any marketing attempts. I believe the Judge made it clear if they plan on marketing EPANOVA, they have to notify Amarin. The battle will resume.
Well AZN will have a big battle ahead, AZN lost the first battle. So even if the results are half way decent. They still have another hurtle to jump, patent infringement.
Well the patent provides protect for a longer period than FDA can provide like NCE protection etc. The patents are very important because the FDA will have them listed in the Orange Book. The question is when Amarin submits the sNDA? Will Vascepa be approved for weight loss if included in submission.
This could be very big in the long run! I hope we see the information released from Reduce-It results soon. Weight Loss has not been publicized yet from what I have seen.
Looks like our hypothesis was correct - Vascepa will have a huge market as a weight loss pill. Nice discovery - thanks!
I suggest you read the rule - please define a long time! Amarin insiders do not have to sell after they exercise options!
Certainly makes sense
Pfizer? may want to make Amarin a subsidiary. A possible scenario and keep management and other employee's active rather than rock the boat. If it's Pfizer, we will become Pfizer share holders and Pfizer the holding company. The thing is, if they were in the process of a sale, not likely management would sell options at the lower market price. After a buyout they would most likely be locked out from selling shares for a year on the open market. Management including myself were on this restriction when our Biomedical company was purchase, it was a private company at the time. The buyer was a public company.
Just ask Kiwi how he feels about his injections.
Not looking likely, as much as I would like it to happen.
Yes Amarin and the press. Tit for Tat..I think Amarin Docs can play the same game. Payback of sorts.
And I'd laugh my ass off. An LDL-L increase in placebo would be the icing on the cake.
Hell I wish I had BC/BS still, they at least had Vascepa Tier 2 and never questioned the PCP about off label script.
Welcome to the enemy - many out there don't want to believe what should have been obvious years ago. I guess he dismissed the Jelis not to mention many smaller EPA based trials like Cherry.
Goes to show how stupid the experts really can be.
Glad to here that news, by any chance do you know if United changed their TIER Level for Vascepa. I believe they are Tier 3. I am ready to have another Anual Physical and renew my Vascepa script - I have Untied Health Care so hope they cover the off label.
The FDA wants to be careful with Amarion regarding First Amendment speech. They don’t want to end up in court again and lose.
Looks like you should try throwing darts, TA just isn't working out. AMRN Price may reach my low target for my buy back sooner than anticipated! :>)
A paradigm shift towards marketing Cardiologist. :>) I Agree T.V ads are a waist of money for now. Certainly under the lowering Triglycerides label.
My reasoning is the market looks at EPS - which I believe will be in negative territory as predicted by the market analyst's. In addition market conditions could change shortly with another government shutdown, plus scripts and hiring will certainly effect EPS. TA often predicts a positive before CC's and then heads south if earnings aren't met. I expect Amarin revenues to be pretty good, not as good as I expected.
So you have to look at the whole picture not just TA. I suggest you try to widen your view. Time is on my side unless a buyout turns into reality. In the mean time the money sits in BOTZ which I like a thematic 'artificial intellegence' fund which has done well since the ~correction.
- B.C.
Yes I throw darts, I didn't say I was committed to buying yesterday. Typically I sell at the higher trading range of PPS and Buy back more shares at a lower price later. I should say a very logical trading method, and have been doing this since it hit $10.
Yesterdays price action and NASDAQ looked good, so I did not buy back. I will wait for the PPS to drop again, which it may do after the up coming CC. Which is almost certain.
Please act a little more mature, when having a discussion. Last Friday you where convinced the price action would be up dramatically from your TA chart, you were totally wrong. Although I had a chance to buy back Tuesday, I was busy working. So I wait like a vulture.
You mean like last Fridays ...
look for this to play out and rocket the share price up and away from danger IMO.
Last week you mention this stock was going up - TA. Followed by "The markets are in fine shape" my take on your words. Actually the market has been in rough shape for a awhile now and volatile. The market was on the nice rise over the last 8-9 years. But the current hype is just that. Hard to say how bad things can get with the new tax tax and trade policies. Time will tell.
Yes BC/BS has always had good coverage of Vascepa Tier 2. They seem to have smart actuaries and know how to save money, at he same time save lives. I not sure what the problem is with outfit's like Kaiser and United Health Care they don't have a clue.
Arn't you the same guy who said the stock price would not budge, even if the results where good for Reduce-It trial. The PPS can move higher or lower for many reasons. Most have nothing to do with the FDA.
It's clear V is becoming the choice of O3's, pure EPA over a mixture. Generic L has lost marketing race. It will get much worse for the generics over the next year.
LMAO....Short AMRN ha ha ha I can't stop laughing....
Nothing Amarin related. Since we are on NASDAQ, better to compare with the NASDAQ index which match AMRN PPS action closely. Weird spike late afternoon related to trade war/tariff news across all exchanges.
Zack's and Motley Fools, these two investment sources have no talent when it comes to analyzing future stock prices.
I think Motley Fools = Motley Morons. Zack's investment hack's. :>)
Well done, I'm glad the appeal worked out. I may have to have my doctor try this approach, if UHC gives me any hassle this year. Perhaps if the insurers pickup on the fact Vascape reduces CVD risk and hospitalization they will update there formulary Tier levels for Vacsepa sooner than later.